Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06776679 · ClinicalTrials.gov registry record · Phase 1
A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants
A Phase 1 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT06776679 is a Phase 1 study that has completed, run by BeiGene. The registered enrollment target is 8 participants.
The verdict
NCT06776679, a Phase 1 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the absorption, metabolism, and excretion of \[14C\]-BGB-16673 and to characterize and determine, where possible, the metabolites present in plasma, urine, and feces in healthy male participants following a single oral administration.
Interventions
- DRUG [14C]-BGB-16673
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2025-01-24 |
| Est. Completion | 2025-03-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06776679
The ClinicalTrials.gov registry entry for NCT06776679 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C]-BGB-16673 is the first listed.
NCT06776679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06776679 about?
NCT06776679 is a clinical study titled "A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants". The purpose of this study is to determine the absorption, metabolism, and excretion of \[14C\]-BGB-16673 and to characterize and determine, where possible, the metabolites present in plasma, urine, and feces in healthy male participants following a single oral administration.
What is the current status of trial NCT06776679?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-01-24. Estimated completion is 2025-03-27.
What interventions are being tested in trial NCT06776679?
The interventions under investigation include: [14C]-BGB-16673 (DRUG).
Who is sponsoring clinical trial NCT06776679?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.